Immatics

Historical price data

Immatics is a clinical-stage biotech company with a mission to develop novel, targeted immunotherapies for solid tumors. Its core achievement is building a dominant, multi-modality pipeline targeting PRAME, an antigen expressed in over 50 cancer types, using its proprietary XPRESIDENT® and XCEPTOR® discovery platforms. The company's strategy is to advance its lead TCR-T cell therapy (IMA203CD8) and bispecific TCR candidates through clinical development, leveraging its transatlantic operational footprint and strategic partnerships to bring precision oncology treatments to a broad patient population.

Proprietary XPRESIDENT® platform for mass spectrometry-based discovery of cancer-specific peptide targets and XCEPTOR® platform for TCR discovery and engineering.

Immatics is the clinical leader in PRAME-targeted therapies, with few direct competitors at a similar stage. It competes broadly with other TCR-focused companies (e.g., Adaptimmune, Immunocore) and CAR-T developers moving into solid tumors. Its proprietary discovery platforms and deep PRAME focus are key differentiators.